Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.

Alhassane DialloMiguel Carlos-BolumbuPr Eric Renard Florence Galtier

Published in: Diabetes, obesity & metabolism (2022)

In T2D patients, treatment effect sizes were greater for kidney than for macrovascular (MACE-3) outcomes, with important differences according to the drugs considered. CKO and MACE-3 are independent. Caution must be taken when interpreting CKO in the absence of MACE-3 data.

Keyphrases

cardiovascular events
end stage renal disease
coronary artery disease
ejection fraction
cardiovascular disease
newly diagnosed
chronic kidney disease
prognostic factors
metabolic syndrome
electronic health record
combination therapy
skeletal muscle
machine learning
smoking cessation